BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Renal Solutions Announces FDA 510(k) Clearance Of The Allient(R) Sorbent Hemodialysis System For Chronic And Acute Hemodialysis


6/8/2006 12:22:27 PM

WARRENDALE, Pa., June 8 /PRNewswire/ -- Renal Solutions, Inc., the exclusive provider of advanced sorbent hemodialysis products and services for treatment of patients with renal failure, announced today that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance of the Allient® Sorbent Hemodialysis System, including the SORB(TM) series and HISORB(TM) series cartridges, for chronic and acute hemodialysis applications. The FDA clearance of the Allient System addresses recent system enhancements which enable improved reliability and performance.

"Our new approval further demonstrates that Renal Solutions is on the leading edge of innovation and improvement in hemodialysis delivery," said Peter M. DeComo, Chairman and CEO of Renal Solutions. "By combining advanced hemocompatible materials in the Pulsar(TM) Blood Pump with the inherent benefits of sorbent therapy, Renal Solutions is poised to introduce new dialysis treatment options with the latest technology," Mr. DeComo stated.

Dr. James Antaki of the Carnegie Mellon University (CMU) Laboratory on Innovation and Optimization of Medical Devices has been closely involved with performance optimization of the Pulsar(TM) Blood Pump. "We are successfully capitalizing on over 20 years of experience in improving multiple aspects of blood pump design and function," said Dr. Antaki. "The unique, pressure- limited, two chamber Pulsar(TM) Pump is the first significant step forward in dialysis blood pump design in several decades," Dr. Antaki continued.

The Allient System opens new treatment options to dialysis professionals and patients by virtue of its ability to provide short, standard or extended duration hemodialysis therapy using just 1 & 1/2 gallons of ordinary drinking water. Numerous clinical studies have shown that an increased cumulative dialysis dose results in better patient outcomes. The Allient System provides the increased dose advantage without the need for an independent water system or large volumes of sterile fluid. This translates into increased transportability, flexibility and ease of system use.

About Renal Solutions, Inc.

www.renalsolutionsinc.com

Renal Solutions, Inc., a medical device and health-care service company, is commercializing a revolutionary technology/service solution for the chronic and acute dialysis market and has a distinct competitive advantage as the exclusive provider of dialysis products and services utilizing sorbent-based toxin removal technology and a unique pressure controlled blood movement system.

This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company's control. Events which could cause results to differ include, failure to meet on-going developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with the FDA/regulatory approval process, adverse changes to reimbursement for the Company's products/services and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time but the Company does not attempt to revise or update its forward- looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.

Source: Renal Solutions, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES